In a surprising turn of events, Regeneron has announced its acquisition of 23andMe for $256 million following the company's bankruptcy. The pharma giant aims to leverage 23andMe's vast customer data for drug discovery while prioritizing privacy and security.
In a dramatic turn of events, 23andMe has filed for Chapter 11 bankruptcy, leading to the immediate resignation of CEO Anne Wojcicki. The company plans to sell its assets while navigating financial turmoil and ongoing efforts to safeguard customer data.
